EUVIMEDEUVIMED entdecken
Crossref

L26/P-680 Ergocalciferol supplementation for systemic inflammation and metabolic profiles in PCOS: a randomized, double-blind, placebo-controlled trial

M. Phunyammalee, S. Indhavivadhana, P. Tanmahasamut, T. Wongwananuruk, P. Chantrapanichkul, M. Rattanachaiyanont

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Phunyammalee und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does weekly ergocalciferol (vitamin D2) supplementation reduce high-sensitivity C-reactive protein (hs-CRP) levels in PCOS women with hypovitaminosis D? Summary answer Weekly 40,000 IU ergocalciferol supplementation effectively normalized vitamin D status but failed to significantly reduce systemic inflammation compared to placebo in women with PCOS What is known already Hypovitaminosis D is common among women with polycystic ovary syndrome (PCOS) and is linked to systemic inflammation and metabolic abnormalities. Although existing research suggests potential benefits from cholecalciferol (D3) supplementation, the efficacy of ergocalciferol (D2) in the context of PCOS remains largely unknown. Study design, size, duration This double-blind, randomized, placebo-controlled trial was conducted at a university hospital in Thailand from June to December 2023. Seventy-eight women with PCOS and hypovitaminosis D were randomized 1:1 to either the treatment group (n = 39) or the control group (n = 39). The intervention duration was 12 weeks. Participants/materials, setting, methods Participants were women aged 18–40 with PCOS (Rotterdam criteria), BMI >23 kg/m2, and 25-hydroxyvitamin D [25(OH)D] <30 ng/mL. The treatment group received vitamin D2 40,000 IU per week, while the control group received a matching placebo. The primary outcome was the change in serum high-sensitivity C-reactive protein (hs-CRP). Secondary outcomes included changes in 25(OH)D, fasting plasma glucose, and lipid profiles. Main results and the role of chance After 12 weeks of intervention, normovitaminosis D (≥30 ng/mL) was achieved by 89.1% of the treatment group versus 0% in the control group (P < 0.01). However, the change in serum hs-CRP levels showed no significant between-group difference (P = 0.40). Similarly, there were no significant improvements in fasting plasma glucose, total cholesterol, triglycerides, or LDL-cholesterol in the treatment group compared to the placebo. No serious adverse events were reported, and compliance was high (>96%) in both groups. These findings suggested that while ergocalciferol is effective for correcting vitamin D insufficiency, it did not elicit immediate anti-inflammatory or metabolic benefits in women with PCOS. Limitations, reasons for caution Limitations include the lack of insulin sensitivity assessment via HOMA-IR and androgen profiles. Furthermore, the 12-week intervention period may have been insufficient to observe subtle or long-term inflammatory and metabolic improvements in this obese PCOS population. Wider implications of the findings Although ergocalciferol (vitamin D2) effectively normalizes vitamin D status, it does not significantly improve systemic inflammation or metabolic markers in women with PCOS. Consequently, vitamin D2 supplementation should be utilized primarily for vitamin D status correction rather than as a primary strategy for long-term risk reduction in this population. Trial registration number Yes

Zitieren

APA

Phunyammalee, M., Indhavivadhana, S., Tanmahasamut, P., Wongwananuruk, T., Chantrapanichkul, P., & Rattanachaiyanont, M. (2026). L26/P-680 Ergocalciferol supplementation for systemic inflammation and metabolic profiles in PCOS: a randomized, double-blind, placebo-controlled trial. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1010

Vancouver

Phunyammalee M, Indhavivadhana S, Tanmahasamut P, Wongwananuruk T, Chantrapanichkul P, Rattanachaiyanont M. L26/P-680 Ergocalciferol supplementation for systemic inflammation and metabolic profiles in PCOS: a randomized, double-blind, placebo-controlled trial. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1010

BibTeX
@article{Phunyammalee2026,
  author = {Phunyammalee, M. and Indhavivadhana, S. and Tanmahasamut, P. and Wongwananuruk, T. and Chantrapanichkul, P. and Rattanachaiyanont, M.},
  title = {L26/P-680 Ergocalciferol supplementation for systemic inflammation and metabolic profiles in PCOS: a randomized, double-blind, placebo-controlled trial},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1010}
}
Kostenlos starten →